SYNRIBO
Total Payments
$287,833
Transactions
29
Doctors
11
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $64,984 | 3 | 0 |
| 2018 | $27.20 | 2 | 2 |
| 2017 | $222,822 | 24 | 9 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $287,608 | 15 | 99.9% |
| Food and Beverage | $225.23 | 14 | 0.1% |
Payments by Type
Research
$287,608
15 transactions
General
$225.23
14 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase II Study of Omacetaxine (OM) in Patients with Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) post Hypomethylating Agent (HMA) Failure | Teva Pharmaceuticals USA, Inc. | $196,443 | 0 |
| Omacetaxine and Bortezomib in Non-Hodgkin's Lymphoma | Teva Pharmaceuticals USA, Inc. | $34,305 | 0 |
| Phase 1b/II Study of Omacetaxine with Cytarabine and Idarubicin Induction Therapy For Patients with de novo Acute Myelogenous Leukemia | Teva Pharmaceuticals USA, Inc. | $33,035 | 0 |
| Omacetaxine Mepesuccinate with Azacitidine for Patients with Previously Untreated Higher Risk Myelodysplastic Syndrome | Teva Pharmaceuticals USA, Inc. | $12,541 | 0 |
| C41443/2057 | Teva Pharmaceuticals USA, Inc. | $11,284 | 2 |
Top Doctors Receiving Payments for SYNRIBO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Atlanta, GA | $284,858 | 13 |
| , MD | Internal Medicine | Tampa, FL | $1,500 | 1 |
| , MD | Internal Medicine | Bloomfield Hills, MI | $1,250 | 1 |
| , MD | Hematology & Oncology | North Bergen, NJ | $91.89 | 5 |
| , M.D | Hematology & Oncology | Brooklyn, NY | $35.67 | 2 |
| , MD | Medical Oncology | Santa Cruz, CA | $20.81 | 1 |
| , M.D | Hematology & Oncology | Alameda, CA | $15.93 | 1 |
| , M.D | Hematology | Grosse Pointe Woods, MI | $14.09 | 1 |
| , M.D | Hematology & Oncology | Los Angeles, CA | $13.60 | 1 |
| , M.D | Hematology & Oncology | La Jolla, CA | $13.60 | 1 |
| , M.D | Hematology & Oncology | Coaldale, PA | $11.91 | 1 |
| , MD | Hematology | Weston, FL | $7.73 | 1 |
Ad
Manufacturing Companies
- Teva Pharmaceuticals USA, Inc. $287,833
Product Information
- Type Drug
- Total Payments $287,833
- Total Doctors 11
- Transactions 29
About SYNRIBO
SYNRIBO is a drug associated with $287,833 in payments to 11 healthcare providers, recorded across 29 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2019. In 2019, $64,984 was paid across 3 transactions to 0 doctors.
The most common payment nature for SYNRIBO is "Unspecified" ($287,608, 99.9% of total).
SYNRIBO is associated with 5 research studies, including "A Phase II Study of Omacetaxine (OM) in Patients with Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) post Hypomethylating Agent (HMA) Failure" ($196,443).